GCM
LGND icon

Graham Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Graham Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$426K Sell
1,349
-157
-10% -$37K 0.01% 763
2026
Q1 		$301K Buy
+1,506
New +$298K 0.01% 813
2025
Q2 		– Sell
-6,052
Closed -$636K – 1463
2025
Q1 		$636K Buy
6,052
+1,054
+21% +$119K 0.01% 709
2024
Q4 		$536K Buy
+4,998
New +$565K 0.01% 712
2024
Q3 		– Sell
-6,040
Closed -$509K – 1226
2024
Q2 		$509K Buy
6,040
+1,183
+24% +$94.1K 0.01% 586
2024
Q1 		$355K Buy
+4,857
New +$358K 0.01% 725
2023
Q1 		– Sell
-5,876
Closed -$393K – 1209
2022
Q4 		$393K Buy
+5,876
New +$382K 0.01% 825

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Graham Capital Management's LGND Position: Q2 2026 in Review

Graham Capital Management reduced its Ligand Pharmaceuticals (LGND) stake by 10% in Q2 2026, selling an estimated $37K and leaving 1,349 shares worth $426K. The position accounts for 0.01% of the portfolio, ranked #763.

Graham Capital Management first reported a position in LGND in Q4 2022 and has held it in 7 quarters since. The position peaked at $636K in Q1 2025. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Graham Capital Management held 1,349 shares of Ligand Pharmaceuticals worth $426K as of Q2 2026.
  • Graham Capital Management sold 157 Ligand Pharmaceuticals shares in Q2 2026, an estimated $37K.
  • Ligand Pharmaceuticals made up 0.01% of Graham Capital Management's portfolio in Q2 2026, its #763 holding.
  • Graham Capital Management first reported a position in Ligand Pharmaceuticals in Q4 2022 and has held it in 7 quarters since.
  • Graham Capital Management's Ligand Pharmaceuticals position peaked at $636K in Q1 2025.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.